Cagri and tirzepatide are often stacked in peptide circles, but cagrilintide is investigational and untested with tirzepatide. Here is what to know.
No, cagri and tirzepatide are not an approved or clinically tested combination. Cagrilintide (commonly shortened to cagri) is an investigational amylin analog that has never been studied with tirzepatide in a published human trial, so the pairing exists only in gray-market peptide circles as a cagri tirz stack. The theory behind it is reasonable, but the safety and dosing data do not exist.
What Cagri (Cagrilintide) Actually Is
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. Amylin is a hormone your pancreas releases alongside insulin after a meal, and it helps you feel full, slows stomach emptying, and blunts glucagon release.
Cagrilintide is engineered to last about a week per injection, similar to how tirzepatide is dosed. It is best known as the "cagri" half of CagriSema, an investigational pairing of cagrilintide plus semaglutide.
Cagrilintide is not FDA-approved for human use in the United States, and it is not sold as a prescription medication. Any cagrilintide sold online is labeled a research chemical, which means it has not been evaluated for purity, sterility, or dosing in people.
How Cagrilintide and Tirzepatide Work Differently
The appeal of a cagri tirz blend comes from the fact that the two compounds act on different hunger pathways. Tirzepatide is a dual GLP-1 and GIP receptor agonist, while cagrilintide targets amylin receptors.
| Feature | Cagrilintide (cagri) | Tirzepatide |
|---|---|---|
| Drug class | Long-acting amylin analog | Dual GLP-1/GIP receptor agonist |
| FDA status | Investigational; not approved for any use | Approved for type 2 diabetes and chronic weight management |
| Typical schedule | Once weekly in research settings | Once weekly |
| Main effects | Satiety, slower gastric emptying, lower glucagon | Appetite suppression, slower gastric emptying, better insulin sensitivity |
| Published combination data | Studied with semaglutide (CagriSema) | No published trial with cagrilintide |
Because the mechanisms overlap in some places and diverge in others, researchers describe the pairing as potentially complementary. That is a hypothesis, not a finding.
Why People Combine Cagri With Tirzepatide
Interest in cagri and tirzepatide together usually traces back to CagriSema headlines. In the REDEFINE 1 trial, cagrilintide plus semaglutide produced roughly 22.7% average weight loss at 68 weeks in adults with obesity.
Many people also assume tirzepatide is a stronger weight-loss agent than semaglutide, so the logic of a cagri tirz peptide stack is simple: if cagri plus semaglutide performs well, cagri plus tirzepatide should perform at least as well.
- The combination targets two separate satiety systems at once.
- Both drugs are dosed once weekly, which makes a blend easy to market.
- Gray-market vendors sell "cagri tirz blend" vials as research products rather than medicines.
It is worth asking what is the difference between semaglutide and tirzepatide compound, because the two are not interchangeable when you compare trial results.
What the Evidence Actually Shows
No published human trial has tested cagrilintide and tirzepatide together. Every claim about the stack is extrapolated from single-agent studies or from CagriSema.
- Tirzepatide (SURMOUNT-1): about 20.9% average weight reduction at 72 weeks with the 15 mg dose.
- Cagrilintide plus semaglutide (REDEFINE 1): about 22.7% average weight reduction at 68 weeks.
- Cagrilintide plus tirzepatide: zero published human data.
There is no established dosing protocol for combining cagrilintide with tirzepatide, and no trial has measured whether the combination is safer or more effective than tirzepatide alone.
The same uncertainty applies to stacking tirzepatide and retatrutide, another investigational triple agonist that people combine on paper long before any trial tests the pairing.
Risks and Side Effects
Both drug classes slow the digestive tract, so their side effects tend to add up rather than cancel out.
- Nausea, vomiting, diarrhea, and constipation are the most commonly reported complaints.
- Additive slowing of gastric emptying can worsen reflux and create a gastroparesis-like picture.
- Pancreatitis and gallbladder disease are rare but serious risks across the GLP-1 class.
- Hypoglycemia is a concern for anyone using insulin or sulfonylureas.
- Rapid weight loss can cost lean muscle mass if protein intake and resistance training are ignored.
Because cagrilintide is unapproved, there is also no way to verify the identity or sterility of a research vial. Reported aod 9604 and tirzepatide together side effects follow the same pattern: mostly anecdotal, rarely documented, and impossible to attribute confidently to one compound.
Dosing, Sourcing, and Legal Status
No validated protocol exists
Online protocols for a cagri tz blend are user-generated. They are not derived from dose-finding studies, and two people following the same chart may absorb very different amounts.
What is actually legal
Tirzepatide is a prescription medicine. Cagrilintide is not approved for any human use, and the FDA has warned that compounded or research-grade GLP-1 products sold online may be misbranded, underdosed, or contaminated.
Sourcing reality
Other popular pairings, such as lipo-c and tirzepatide, follow the same gray-market logic: two injectables sold as research chemicals with no oversight of what is actually in the vial.
A related question, can you take semaglutide and tirzepatide at the same time, has the same answer as the cagri question — not in any supervised clinical setting.
A Safer Way to Think About It
If you are already prescribed tirzepatide, that medication is doing the work that has actual trial data behind it. Adding an unapproved amylin analog on top introduces variables no clinician can monitor properly.
Anyone considering a cagri and tirzepatide combination should talk with a healthcare professional first, especially with a history of pancreatitis, gallbladder problems, kidney disease, or medullary thyroid carcinoma.
The honest summary: the mechanism story is interesting, the human evidence is empty, and the risk of an unregulated injectable is real.
Frequently Asked Questions
Is it safe to stack cagri and tirzepatide?
There is no human safety data for cagrilintide combined with tirzepatide, so no one can say the stack is safe. Both compounds slow gastric emptying, which means nausea, constipation, and reflux risk can stack as well. Research-grade cagrilintide also carries a purity and sterility risk that prescription tirzepatide does not.
What is a cagri tirz blend?
A cagri tirz blend is a vial sold by gray-market peptide vendors that combines cagrilintide and tirzepatide and is labeled for research use only. It is not an FDA-approved product, and there is no standard ratio, concentration, or dosing guidance behind what is sold. Buying it means accepting unknown purity and no regulatory oversight.
Does cagrilintide plus tirzepatide cause more weight loss than tirzepatide alone?
No published trial has compared the combination to tirzepatide alone, so that question is currently unanswered. The closest evidence comes from separate studies: about 20.9% average weight loss with tirzepatide 15 mg at 72 weeks in SURMOUNT-1, and about 22.7% with cagrilintide plus semaglutide at 68 weeks in REDEFINE 1. Those results cannot be transferred to a cagri and tirzepatide stack.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.